TD Cowen Maintains Buy on Humacyte, Lowers Price Target to $1

TD Cowen analyst Joshua Jennings has maintained a 'Buy' rating on Humacyte (NASDAQ: HUMA) but has lowered the price target from $3.5 to $1. This adjustment reflects a significant change in the expected valuation of the company.